natgillin/translations-raw huggingface dataset:
OTHER SPECIAL WARNING IF NECESSARY Cytotoxic 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Citotoksično zdravilo.
Occurrence of VOD was not related to overexposure. 
Pogostnost veno-okluzivne bolezni (VOD) ni bila povezana s preveliko izpostavljenostjo.
Polycarbonate syringes must not be used with busulfan. 
Pri uporabi busulfana se ne sme uporabljati polikarbonatnih brizg.
At 2 years, the cumulative incidence of NRM was 11.3% (95%CI, 5.5-19.3%), and that of relapse or progression from allo-HCT was 43.8% (95CI, 31.1-55.7%). 
Po dveh letih je bila kumulativna incidenca UNP 11,3 % (95 % IZ: od 5,5 do 19,3 %) in recidiva ali napredovanja od homologne transplantacije hematopoetskih celic 43,8 % (95 % IZ: od 31,1 do 55,7 %).
followed by: - 4 cycles of 50 mg/kg body weight (BW) cyclophosphamide (BuCy4) or - one administration of 140 mg/m² melphalan (BuMel) initiated for at least 24 hours following the 16th dose of busulfan (see section 4.5). 
Temu sledijo: - 4 cikli po 50 mg/kg telesne mase (TM) ciklofosfamida (BuCy4) ali - en odmerek 140 mg/m2 melfalana (BuMel), ki se začnejo vsaj 24 ur po 16. odmerku busulfana (glejte poglavje 4.5).
Leukaemia patients treated with busulfan developed many different cytological abnormalities, and some developed carcinomas. 
Pri bolnikih z levkemijo, ki so bili zdravljeni z busulfanom, se je razvilo mnogo različnih citoloških sprememb, pri nekaterih je nastal karcinom.
Severe granulocytopenia, thrombocytopenia, anaemia, or any combination thereof may develop. 
Razvije se lahko huda granulocitopenija, trombocitopenija, anemija ali katera koli kombinacija naštetega.
The World Health Organisation has concluded that there is a causal relationship between busulfan exposure and cancer. 
Svetovna zdravstvena organizacija (WHO) je ugotovila, da obstaja vzročna povezava med izpostavljenostjo busulfanu in rakom.
Busulfan Fresenius Kabi is a potent cytotoxic medicine that results in profound decrease of blood cells. 
Zdravilo Busulfan Fresenius Kabi je močno citotoksično zdravilo, ki zelo zmanjša število krvnih celic.
Caution should be exercised when using paracetamol prior to (less than 72 hours) or concurrently with busulfan due to a possible decrease in the metabolism of busulfan (See section 4.5). 
Pri predhodni (manj kot 72-urni) ali sočasni uporabi paracetamola z busulfanom morate biti previdni zaradi možne zmanjšane presnove busulfana (glejte poglavje 4.5).
Busulfan in combination with fludarabine (FB) In adults The recommended dose and schedule of administration is: - fludarabine administered as a single daily one-hour infusion at 30 mg/m² for 5 consecutive days or 40 mg/m² for 4 consecutive days. 
Busulfan v kombinaciji s fludarabinom (FB) Odrasli Priporočeni odmerek in razpored uporabe sta: - Fludarabin v enourni infuziji v enkratnem dnevnem odmerku 30 mg/m2, 5 dni zapored ali 40 mg/m2, 4 dni zapored.
The concomitant systemic administration of phenytoin to patients receiving high-dose of oral busulfan has been reported to increase busulfan clearance, due to induction of glutathion-S-transferase whereas no interaction has been reported when benzodiazepines such as diazepam, clonazepam or lorazepam have been used to prevent seizures with high-dose busulfan. 
Poročali so, da sočasna sistemska uporaba fenitoina pri bolnikih, ki prejemajo visoke peroralne odmerke busulfana, poveča očistek busulfana zaradi indukcije glutation-S-transferaze,medtem ko pri uporabi benzodiazepinov, kot so diazepam, klonazepam ali lorazepam, za preprečevanje epileptičnih napadov pri visokih odmerkih busulfana, niso poročali o nikakršnih interakcijah.
Busulfan administration should be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation. 
Uporabo busulfana mora nadzorovati zdravnik, izkušen v pripravljalnih terapijah pred transplantacijo hematopoetskih progenitorskih celic.
WHO has concluded that there is a causal relationship between busulfan exposure and cancer. 
WHO je ugotovila, da obstaja vzročno razmerje med izpostavljenostjo busulfanu in rakom.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements for cytotoxic medicinal products. 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi za citotoksična zdravila.
You should tell your doctor: - if you have a liver, kidney, heart or lung problem, - if you have a history of seizures, - if you are currently taking other medicines. 
- imate težave z jetri, ledvicami, srcem ali pljuči, - ste kdaj imeli epileptične napade, - trenutno jemljete druga zdravila.
During clinical trials with intravenous busulfan administered as 0.80 mg/kg four-times daily, 90% of patients AUCs were below the upper AUC limit (1500 µmol/L.minute) and at least 80% were within the targeted therapeutic window (900 - 1500 µmol/L.minute). 
Med kliničnimi preskušanji z intravensko uporabo busulfana v odmerku 0,80 mg/kg, štirikrat dnevno, je bilo 90 % bolnikov pod zgornjo mejo AUC (površine pod krivuljo) (1.500 µmol/l·min) in vsaj 80 % bolnikov je bilo znotraj ciljnega terapevtskega območja (med 900 in 1.500 µmo/l·min).
Patients received a conditioning regimen based on the administration of fludarabine immediately followed by single daily dose of 3.2 mg/kg busulfan over 2 or 3 consecutive days. 
Bolniki so prejemali pripravljalno shemo na podlagi uporabe fludarabina, ki mu je takoj sledil enkraten dnevni odmerek 3,2 mg/kg busulfana, v 2 ali 3 dneh zapored.
The 2-year OS rate was 61.9% (95%CI, 51.1-72.7%)]. 
Dveletni delež celokupnega preživetja je bil 61,9 % (95 % IZ: od 51,1 do 72,7 %).
Interstitial lung disease** 
Intersticijska bolezen pljuč**
Documentation on the safety and efficacy of busulfan in combination with cyclophosphamide in the BuCy2 regimen prior to conventional allogeneic and/or autologous HPCT derives from two clinical trials (OMC-BUS-4 and OMC-BUS-3). 
Dokumentacija o varnosti in učinkovitosti busulfana v kombinaciji s ciklofosfamidom v terapiji BuCy2 pred konvencionalno alogensko in/ali avtologno HPCT izhaja iz dveh kliničnih preskušanj (OMC-BUS4 in OMC-BUS-3).
Busulfan following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen. 
Busulfan po fludarabinu (FB) je indiciran kot pripravljalno zdravljenje pred transplantacijo hematopoetskih progenitorskih celic (HPCT) pri odraslih bolnikih, ki so kandidati za pripravljalno shemo zmanjšane intenzivnosti (RIC - reduced-intensity conditioning).
The analysis of data through a population pharmacokinetic method indicated no difference on intravenous busulfan clearance between phenytoin and clonazepam based therapy and therefore similar busulfan plasma exposures were achieved whatever the type of seizure prophylaxis. 
Analiza podatkov z metodo populacijske farmakokinetike je pokazala, da ni razlik v očistku intravensko uporabljenega busulfana pri zdravljenju, ki temelji na fenitoinu ali klonazepamu, torej so pri obeh vrstah preprečevanja epileptičnih napadov bile dosežene podobne izpostavitve busulfanu v plazmi.
In adults Busulfan Fresenius Kabi is used in combination with cyclophosphamide or fludarabine. 
Pri odraslih se zdravilo Busulfan Fresenius Kabi uporablja v kombinaciji s ciklofosfamidom ali fludarabinom.
The malformations included serious heart and/or major vessels anomalies: a common truncus arteriosis and no ductus arteriosis, coarctation of the pulmonary trunk and the pulmonary arteries, intraventricular defects of the heart. 
Med malformacije so sodile resne anomalije srca in/ali velikih žil: truncus arteriosis in odsotnost Botallovega voda, koarktacija pljučnega debla in pljučnih arterij ter intraventrikularne okvare srca.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 8 vials of 10 ml 60 mg per vial 
FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje 8 vial po 10 ml
DMA decreases fertility in male and female rodents. 
DMA zmanjšuje plodnost samcev in samic pri glodavcih.
- Busulfan will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days. 
- Busulfan je treba uporabiti v enkratnem dnevnem odmerku 3,2 mg/kg v 3-urni infuziji, takoj po fludarabinu, 2 ali 3 dni zapored.
You will receive this preparative medicine before receiving a transplant of either bone marrow or haematopoietic progenitor cell. 
To zdravilo boste prejeli kot pripravljalno terapijo pred presaditvijo kostnega mozga ali krvotvornih progenitorskih celic.
Veno occlusive disease (VOD) was reported in 15% (4/27) and 7% (2/28) of the autologous and allogenic transplant respectively. 
Pri 15 % (4/27) bolnikov z avtologno in pri 7 % (2/28) bolnikov z alogensko transplantacijo so poročali o veno-okluzivni bolezni (VOD).
A single s.c. dose of 2.2 g/kg administered on gestation day 4 terminated pregnancy in 100% of tested hamster. 
Enkratni subkutani odmerek 2,2 g/kg v četrtem dnevu brejosti je prekinil brejost pri 100 % testiranih samic hrčkov.
Thrombocytopenia (< 25x109/l or requiring platelet transfusion) occurred at a median of 5-6 days in 98% of patients. 
Trombocitopenija (< 25 x 109/l ali zahtevana transfuzija trombocitov) se je pojavila mediano 5-6 dni pri 98 % bolnikov.
Busulfan is metabolised mainly through conjugation with glutathione (spontaneous and glutathione-S-transferase mediated). 
Busulfan se presnavlja predvsem preko konjugacije z glutationom (spontano ali pa pod vplivom glutation-S-transferaze).
* reported in post-marketing experience ** include haemorrhagic cystitis induced by viral infection 
* objavljeno v obdobju, ko je zdravilo že na trgu ** vključuje hemoragični cistitis, povzročen z virusno okužbo
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) solution for injection has been demonstrated for: 
Kemijska in fizikalna stabilnost med uporabo, po redčenju s 5 % raztopino glukoze ali 0,9 % raztopino natrijevega klorida (9 mg/ml) za injiciranje, sta dokazani:
OUTER CARTON containing 8 vials 
PODATKI NA ZUNANJI OVOJNINI ZUNANJI KARTON, ki vsebuje 8 vial
In adult and paediatric studies, patients received either phenytoin or benzodiazepines as seizure prophylaxis treatment (see sections 4.4 and 4.5). 
V študijah pri odrasli in pediatrični populaciji so bolniki kot profilakso proti epileptičnim napadom preventivno prejemali fenitoin ali benzodiazepine (glejte poglavji 4.4 in 4.5).
- the contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent. 
- vsebino brizge morate prestaviti v vrečko (ali brizgo) za intravensko uporabo, v katero ste prej že dali izračunano količino izbranega redčila.
Serious toxicities involving the hepatic and respiratory systems were considered as expected consequences of the conditioning regimen and transplant process. 
Resne toksične učinke, ki vplivajo na jetrni in respiratorni sistem, so smatrali kot pričakovane posledice pripravljalne terapije in transplantacijskega procesa.
Serious toxicities involving the haematologic, hepatic and respiratory systems were considered as expected consequences of the conditioning regimen and transplant process. 
Resne toksične učinke, ki vplivajo na hematološki, jetrni in respiratorni sistem, so upoštevali kot pričakovane posledice pripravljalne terapije in transplantacijskega procesa.
• Quantity of Busulfan Fresenius Kabi: 
• Količina zdravila Busulfan Fresenius Kabi:
In adults, for the FB regimen, published studies did not report any mutual drug-drug interaction between intravenous busulfan and fludarabine. 
V objavljenih študijah s shemo FB pri odraslih niso zabeležili nobenega medsebojnega delovanja med intravenskim busulfanom in fludarabinom.
Busulfan should be administered by intravenous infusion via central venous catheter. 
Busulfan je potrebno dajati intravensko, skozi osrednji venski kateter.
The Kaplan-Meier estimate of DFS at 2 years was 49.9% (95%CI, 32.6-72.7). 
Ocena 2-letnega preživetja brez bolezni (DFS) po Kaplan-Meierju je bila 49,9 % (95 % IZ: od 32,6 do 72,7 %).
However a higher variability was observed in children < 9 kg leading to 60% of children achieving the therapeutic window (900 - 1500 µmol/L.minute). 
Pri otrocih s telesno maso < 9 kg je bila opažena večja variabilnost, ki je povzročila, da je 60 % otrok doseglo terapevtsko okno (900-1500 µmol/l·min).
Busulfan Fresenius Kabi can also produce symptoms of menopause and in pre-adolescent girls it can prevent the onset of puberty. 
Zdravilo Busulfan Fresenius Kabi lahko izzove tudi znake menopavze in lahko prepreči začetek pubertete pri deklicah.
Patients received doses of 0.8 mg/kg busulfan every 6 hours infusion for a total 16 doses followed by cyclophosphamide at 60 mg/kg once per day for two days (BuCy2 regimen). 
Bolniki so prejemali odmerke po 0,8 mg/kg busulfana, na vsakih 6 ur z infuzijo, do skupno 16 odmerkov, ki so jim sledili odmerki 60 mg/kg ciklofosfamida enkrat dnevno, 2 dni (terapija BuCy2).
- 8 hours (including infusion time) after dilution when stored at 25°C ± 2°C 
- do 8 ur (vključno s časom infuzije) po redčenju, če je bila raztopina shranjena pri temperaturi
Do not use Busulfan Fresenius Kabi: - if you are allergic to busulfan or any of the other ingredients of this medicine listed in section 6. 
Ne uporabljajte zdravila Busulfan Fresenius Kabi: - če ste alergični na busulfan ali katero koli drugo sestavino tega zdravila, navedeno v poglavju 6, - če ste noseči ali menite, da bi lahko bili noseči.
The recommended posology for children as detailed in section 4.2 enabled over 70% up to 90% of children ≥ 9kg in achieving the therapeutic window (900 - 1500 µmol/L.minute). 
Priporočeno odmerjanje zdravila pri otrocih je podrobno navedeno v poglavju 4.2 in omogoča, da od 70 % do 90 % otrok s telesno maso ≥9 kg doseže terapevtsko okno (900-1500 µmol/l·min).
Adverse reactions information are derived from the clinical study in paediatrics (n=55). 
Informacije o neželenih učinkih so pridobljene iz pediatrične klinične študije (n = 55).
The incidence of acute graft versus host disease (a-GVHD) data was collected in OMC-BUS-4 study (allogeneic)(n=61) . 
Podatki o pojavljanju akutne reakcije presadka proti gostitelju (acute graft-versus-host diseaseaGVHD) so bili zbrani v raziskavi OMC-BUS-4 (alogenska) (n = 61).
Cardiac: changes and abnormalities in heart rhythm, fluid retention or inflammation around the heart, decrease heart output. 
Srce: spremembe in nepravilnosti srčnega utripa, zadrževanje tekočine ali vnetje okrog srca, zmanjšan srčni iztis.
Before receiving Busulfan Fresenius Kabi, you will be medicated with - anticonvulsive medicines to prevent seizures (phenytoin or benzodiazepines) and - antiemetic medicines to prevent vomiting. 
Zdravila, ki jih boste prejeli pred uporabo zdravila Busulfan Fresenius Kabi: Preden boste prejeli zdravilo Busulfan Fresenius Kabi, boste prejeli še: - antikonvulzivna zdravila, za preprečitev epileptičnih napadov (fenitoin ali benzodiazepine) in - antiemetična zdravila, za preprečitev bruhanja.
Busulfan Fresenius Kabi destroys the original bone marrow before the transplant. 
Zdravilo Busulfan Fresenius Kabi uniči izvorni kostni mozeg bolnika pred presaditvijo.
In paediatric population, absolute neutrophil counts < 0.5x109/l at a median of 3 days post transplant occurred in 100% of patients and lasted 5 and 18.5 days in autologous and allogeneic transplant respectively. 
Pri pediatrični populaciji se je absolutno število nevtrofilcev < 0,5x109/l mediano 3 dni po transplantaciji pojavilo pri 100 % bolnikov in je trajalo 5 dni pri avtologni ter 18,5 dneva pri alogenski transplantaciji.
Renal: increase in creatinine elimination, discomfort in urination, and decrease in urine output and bloody urine. 
Ledvice: povečanje kreatininskega očistka, bolečine pri uriniranju, zmanjšana količina urina in kri v urinu.
Busulfan is administered as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses prior to cyclophosphamide or melphalan and haematopoietic progenitor cell transplantation (HPCT). 
Busulfan se uporablja v obliki 2-urne infuzije na 6 ur, 4 zaporedne dni, kar je skupaj 16 odmerkov pred uporabo ciklofosfamida ali melfalana in pred transplantacijo hematopoetskih progenitorskih celic.
Documentation of the safety and efficacy of busulfan in combination with cyclophosphamide in the BuCy4 or with melphalan in the BuMel regimen prior to conventional allogeneic and/or autologous HPCT derives from clinical trial F60002 IN 101 G0. 
Dokumentacija o varnosti in učinkovitosti busulfana v kombinaciji s ciklofosfamidom v terapiji BuCy4 ali melfalanom v terapiji BuMel pred konvencionalnim alogensko in/ali avtologno HPCT izhaja iz kliničnega preskušanja F60002 IN 101 G0.
Cardiac: clotting of femoral artery, extra heart beats, decrease in heart rate, diffuse leak of fluid from the capillaries (small blood vessels). 
Srce: zamašitev femoralne arterije, dodatni utripi srca, zmanjšan srčni utrip, difuzno prepuščanje tekočine iz kapilar (majhne krvne žile).
Busulfan Fresenius Kabi may interact with other medicines. 
Zdravilo Busulfan Fresenius Kabi lahko medsebojno učinkuje z drugimi zdravili.
The incidence of acute graft versus host disease (a-GVHD) data was collected in allogeneic patients (n=28). 
Podatki o pojavnosti akutne reakcije presadka proti gostitelju (acute graft-versus-host diseaseaGVHD) so bili zbrani pri alogenskih bolnikih (n = 28).
Busulfan is administered prior to the haematopoietic progenitor cell transplantation (HPCT). 
Busulfan se daje pred transplantacijo hematopoetskih progenitorskih celic (HPCT).
The medicinal product is not recommended in obese children and adolescents with body mass index Weight (kg)/ (m2) > 30 kg/m² until further data become available. 
Dokler ne bodo na voljo dodatni podatki, uporaba tega zdravila pri debelih otrocih in mladostnikih z indeksom BMI (masa (kg)/višina (m2)) > 30 kg/m2 ni priporočljiva.
The amount of Busulfan Fresenius Kabi and diluent to be administered would be calculated as follows: for a patient with a Y kg body weight: 
Količino zdravila Busulfan Fresenius Kabi in redčila za uporabo lahko izračunamo na naslednji način:za bolnika, ki tehta Y kg:
In this study, all, but one, patients engrafted, at a median of 15 (range, 10-23) days after allo-HCT. 
V tej študiji je do vsaditve (engraftment) prišlo pri vseh bolnikih, razen pri enem, in sicer po mediano 15 dneh (razpon: od 10 do 23) po homologni transplantaciji hematopoetskih celic.
The pharmacokinetics of busulfan has been investigated. 
Raziskovali so farmakokinetiko busulfana.
• The diluted solution must be mixed thoroughly by inverting several times. 
• Vrečko z razredčeno raztopino morate temeljito premešati z nekajkratnim obračanjem.
Women must stop breast-feeding before starting their treatment with Busulfan Fresenius Kabi. 
Ženske morajo prekiniti z dojenjem pred začetkom zdravljenja z zdravilom BusulfanFreseniua Kabi.
One ml of concentrate contains 6 mg busulfan (60 mg in the vial). 
En ml koncentrata vsebuje 6 mg busulfana (60 mg v eni viali).
The safety profile of busulfan combined with fludarabine (FB) has been examined through a review of adverse reactions reported in published data from clinical trials in RIC regimen. 
Varnostne značilnosti busulfana v kombinaciji s fludarabinom (FB) so raziskali s pregledom neželenih učinkov, opisanih v objavljenih podatkih kliničnih preskušanj, v katerih so uporabljali pripravljalno shemo zmanjšane intenzivnosti (RIC).
Renal and urinary disorders It has been suggested that conditioning regimens containing fludarabine were associated with higher incidence of opportunistic infections after transplantation because of the immunosuppressive effect of fludarabine. 
Domnevno naj bi bile pripravljalne sheme s fludarabinom po transplantacijah povezane z višjo incidenco oportunističnih okužb, ker fludarabin deluje imunosupresivno.
Busulfan will be administered once daily during 2 or 3 consecutive days prior to transplant. 
- Zdravilo Busulfan Fresenius Kabi boste prejemali enkrat dnevno, 2 ali 3 dni zaporedoma pred presaditvijo.
Myelo-suppression and immuno-suppression were the desired therapeutic effects of the conditioning regimen and consequently were not considered undesirable effects. 
Želena terapevtska učinka pripravljalne sheme sta bila mielosupresija in imunosupresija, ki zato nista bila obravnavana kot neželena učinka.
The treatment-related mortality/non-relapse mortality (TRM/NRM) reported until day+100 posttransplant has also been examined through a review of published data from clinical trials. 
Prav tako so s pregledom objavljenih podatkov kliničnih preskušanj proučili z zdravljenjem povezano umrljivost/umrljivost, nepovezano s ponovitvijo bolezni (ZPU/UNP), zabeleženo do dneva + 100 po transplantaciji.
Hepato-biliary disorders VOD was reported with a range between 3.9% and 15.4%. 
Bolezni jeter, žolčnika in žolčevodov: O veno-okluzivni bolezni so poročali v razponu med 3,9 in 15,4 %.
This study demonstrated that bodyweight was the predominant covariate to explain the busulfan pharmacokinetic variability in children over body surface area or age. 
Ta študija je pokazala prevladujoč vpliv telesne mase v primerjavi s vplivom telesne površine ali starosti, na farmakokinetično variabilnost busulfana pri otrocih.
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109/l was 21 days (range 12-47 days) in allogenic patients, and 11 days (range 10-15 days) in autologous patients. 
Čas za dosego absolutnega števila nevtrofilcev, večjega od 0,5 x 109/l, je bil pri alogenskih bolnikih 21 dni (v razponu 12-47 dni), pri avtolognih bolnikih pa 11 dni (v razponu 10-15 dni).
Special caution should be exercised when administering the recommended dose of busulfan to patients with a history of seizures. 
Posebna previdnost pri uporabi priporočenega odmerka busulfana je potrebna pri bolnikih z anamnezo epileptičnih napadov.
The recommended dose of Busulfan Fresenius Kabi in combination with cyclophosphamide or melphalan is based on your body weight varying between 0.8 and 1.2 mg/kg. 
Priporočeni odmerek zdravila Busulfan Fresenius Kabi v kombinaciji s ciklofosfamidom ali melfalanom je odvisen od telesne mase in je v razponu med 0,8 in 1,2 mg/kg.
Total clearance in plasma ranged 2.25 - 2.74 ml/minute/kg. 
Skupni plazemski očistek je bil med 2,25 in 2,74 ml/min/kg.
• Quantity of diluent: 
• Količina redčila:
Overall mortality and non-relapse mortality at more than 100 days post-transplant was (8/61) 13% and (6/61) 10% in allotransplanted patients, respectively. 
Pri alogenskih bolnikih je bila celokupna smrtnost pri več kot 100 dnevih po transplantaciji 13-odstotna (8/61), smrtnost, ki ni bila povezana s ponovitvijo bolezni, pa 10-odstotna (6/61).
Renal: increase in the amount of nitrogen components in the blood stream, moderate renal insufficiency, renal disorder. 
Ledvice: povečana količina dušikovih spojin v krvnem obtoku, zmerno zmanjšano delovanje ledvic, ledvična motnja.
Antiemetics should be administered prior to the first dose of busulfan and continued on a fixed schedule according to local practice through its administration. 
Pred prvim odmerkom busulfana morajo bolniki prejeti antiemetike in nadaljevati z njihovo uporabo po vnaprej določeni shemi odmerjanja, skladni z lokalno prakso, ves čas uporabe busulfana.
Busulfan is a potent cytotoxic agent and a bifunctional alkylating agent. 
Busulfan je močna citotoksična in bifunkcionalno alkilirajoča učinkovina.
Frequent complete blood counts, including differential white blood cell counts, and platelet counts should be monitored during the treatment and until recovery is achieved. 
Med zdravljenjem ter do končne ozdravitve je potrebno pogosto nadzorovati celotno krvno sliko, vključno z diferencialno sliko belih krvnih celic in trombocitov.
Busulfan in combination with cyclophosphamide or melphalan In adults 
Busulfan v kombinaciji s ciklofosfamidom ali melfalanom Odrasli